Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST‐2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we present a ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Pemmaraju, Naveen, Harrison, Claire, Gupta, Vikas, Verstovsek, Srdan, Scott, Bart, Oh, Stephen T., Palandri, Francesca, Al‐Ali, Haifa Kathrin, Sobas, Marta, McMullin, Mary Frances, Mesa, Ruben, Buckley, Sarah, Roman‐Torres, Karisse, Vannucchi, Alessandro, Yacoub, Abdulraheem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713029/
https://www.ncbi.nlm.nih.gov/pubmed/36467816
http://dx.doi.org/10.1002/jha2.591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713029/
https://www.ncbi.nlm.nih.gov/pubmed/36467816
http://dx.doi.org/10.1002/jha2.591

Ejemplares similares